Alpha-gal Syndrome
Alpha-gal Syndrome - Related Videos
13:34
Gene Trapping Using Gal4 in Zebrafish
0 Views •
Cited by 19 •
2013
This protocol describes the method of gene trap insertional mutagenesis using Gal4-VP16 as the primary reporter and GFP/RFP as secondary reporters in zebrafish. Approximately one in ten high-expressing F0 fish yield gene trap progeny co-expressing GFP and RFP. The screening procedure can be readily scaled to adapt to the size of the laboratory performing the insertional mutagenesis screen.
08:31
Conscious and Non-conscious Representations of Emotional Faces in Asperger's Syndrome
0 Views •
Cited by 5 •
2016
An EEG experimental protocol is designed to clarify the interplay between conscious and non-conscious representations of emotional faces in patients with Asperger's syndrome. The technique suggests that patients with Asperger's syndrome have deficits in non-conscious representation of emotional faces, but have comparable performance in conscious representation with healthy controls.
06:29
Using the GAL4-UAS System for Functional Genetics in Anopheles gambiae
0 Views •
Cited by 11 •
2021
The bipartite GAL4-UAS system is a versatile tool for modification of gene expression in a controlled spatiotemporal manner which permits functional genetic analysis in Anopheles gambiae. The procedures described for using this system are a semi-standardized cloning strategy, sexing and screening of pupae for fluorescent protein markers and embryo fixation.
01:30
Detection of Phosphorylated Alpha-Synuclein Using Western Blotting
0 Views •
2025
Add a loading buffer containing a detergent, a reducing agent, and a tracking dye.
03:25
Immunostaining of Neurons Treated with Alpha-Synuclein Aggregates
0 Views •
2025
This video demonstrates the immunostaining of neurons treated with alpha-synuclein (αS) aggregates. The neurons are first treated with αS aggregates. They are then fixed, permeabilized, and treated with a blocking solution. Primary antibodies are added, followed by a fluorescently labeled secondary antibodies and a nuclear stain. The sample is then mounted and observed under a microscope.
FAQs
The delay is a defining clinical feature of the immune response described for Alpha-gal Syndrome. Symptoms commonly appear several hours after exposure to a relevant mammalian product, rather than immediately. This timing can make the connection between exposure and illness difficult to recognize, so clinical assessment must consider both the patient’s symptoms and the interval before they began.
Sensitization produces IgE antibodies that specifically recognize alpha-gal. When a sensitized person encounters the carbohydrate again, those antibodies can activate mast cells and basophils, immune cells associated with allergic reactions. Their activation helps explain why exposure may lead to hives, gastrointestinal symptoms, respiratory distress, or anaphylaxis, with severity differing among patients.
A tick bite can serve as the sensitizing event that initiates production of alpha-gal-specific IgE. This links the ecology of ticks with antibody-mediated hypersensitivity: an environmental exposure changes immune reactivity, and later contact with certain mammalian materials can provoke symptoms. Consequently, AGS provides a model for studying how infection-related ecology can influence allergic disease.
Evaluation should account for delayed symptoms, possible contact with mammalian meat, dairy, gelatin, or other animal-derived materials, and the clinical pattern after exposure. Relevant outcomes range from hives and gastrointestinal symptoms to respiratory distress or anaphylaxis. Because triggers and severity vary among patients, assessment should not rely on a single symptom or exposure pattern.
Risk management must reflect the patient’s own trigger profile and the potential severity of reactions. The relevant exposure range includes food products and other animal-derived materials, while outcomes may extend from skin or gastrointestinal symptoms to respiratory distress or anaphylaxis. Recognizing this variability supports a patient-specific approach rather than assuming identical risks for everyone with AGS.
AGS connects several fields that are often considered separately: tick-associated exposure, immune sensitization, IgE-mediated hypersensitivity, clinical recognition, and risk management. Its study helps researchers examine how an environmental event can produce a specific antibody response and how that response later affects reactions to mammalian materials. It also highlights infection ecology as relevant to allergic disease.